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Abstract Several plant-derived polysaccharides have been
shown to have anti-inﬂammatory activity in animal models.
Ambrotose complex and Advanced Ambrotose are dietary
supplements that include aloe vera gel, arabinogalactan,
fucoidan, and rice starch, all of which have shown such
activity. This study was designed to evaluate these formu-
lations against dextran sulfate sodium (DSS)-induced colitis
in rats and to conﬁrm their short-term safety after 14 days of
daily dosing. Rats were dosed daily orally with vehicle,
Ambrotose or Advanced Ambrotose. On day six groups of
rats received tap water or 5% Dextran Sulfate sodium.
Ambrotose and Advanced Ambrotose signiﬁcantly lowered
the disease scores and partially prevented the shortening of
colon length. An increase in monocyte count was induced by
dextran sulfate sodium and inhibited by Ambrotose and
Advanced Ambrotose. There were no observable adverse
effects after 14-day daily doses. The mechanism of action of
the formulations against DSS-induced colitis may be related
to its effect on monocyte count.
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Introduction
Several plant-derived polysaccharides have been shown to
be effective in animal colitis models or IBD. Ambrotose
complex (AMB) and Advanced Ambrotose powder
(AdvAMB) are dietary supplement formulas that include
these plant-derived polysaccharides. AdvAMB also con-
tains galactofucan sulfate (fucoidan). Aloe [1, 2], arabi-
nogalactan [3], fucoidan [4], rice starch [5] and
glucosamine [6] have all been shown to have activity in
animal colitis models. AMB and AdvAMB provide a good
source of dietary ﬁber and immune system function [7] that
can positively inﬂuence both gastrointestinal health and
may have additional pharmacological activity due to the
various polysaccharide components. Therefore it was of
interest to evaluate the potential for AMB and AdvAMB
for inhibitory activity in a rat model of colitis.
AMB can be digested by human colonic bacteria into
lower molecular weight oligo- and monosaccharide and
may then be absorbed through the intestinal mucosa [8].
The exact mechanism(s) of action of AMB products have
not been established. Schley and Field [7] showed that
dietary ﬁbers and probiotics have immune-enhancing
effects. Mannans and related complex carbohydrates have
also been observed to stimulate immune response by acti-
vation of macrophages and stimulation of T cells [9]. The
addition of soluble mannans reduces myeloperoxidase-
mediated killing in a dose dependent manner [10]. Studies
have shown that probiotics administered to patients with
inﬂammatory bowel disease have a positive effect [11].
Dextran Sulfate Sodium (DSS)-induced colitis has been
shown to be a good model for inﬂammatory bowel disease
(IBD).Itproducessigniﬁcantcolonicpathologicalchangesin
mice [12] and rats [13]. Studies have also shown that agents
effective clinically are also effective in this model [14, 15].
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ease and comprises a family of diseases affecting both
small and large intestines. The etiology is still unknown;
however, several factors have been implicated in both the
initiation and continuation of the pathology [16]. Current
treatment consists of acute and maintenance dosing. Cor-
ticosteroids, aminosalicylate, immunomodulatory agents,
antibiotics and anti-TNFc antibodies have all been used
with limited success. Complementary and alternative
therapy for IBD has been reviewed recently by Langmead
and Rampton [17].
This study was designed to assess the possible protective
effect of AMB and AdvAMB against DSS-induced colitis
using prevention of colonic shortening and reduction of the
Disease Activity Index. Terminal blood samples were also
taken to evaluate any potential effects on blood cell count,
clinical chemistry and lipid proﬁle. A second arm of the
study was designed to evaluate their short-term safety.
AMB and AdvAMB were evaluated at doses comparable
to, and ten times higher than, doses used in humans.
Polysaccharide dosing prior to induction of DSS-induced
colitis was used.
Methods
Selection of Animals One hundred healthy male Sprague-
Dawley rats (Ace Animals, Boyertown, PA.) were weighed
and assigned randomly to ten groups. The rats were
acclimated to the housing facilities for 3 days prior to
testing. The protocols were approved by the EPSL Insti-
tutional Animal Care and Use Committee.
Dosing All doses were administered daily on an mg/kg
basis. Each animal was dosed in the morning, starting on
day 0, by the oral route using a ball tipped needle attached
to the appropriate size syringe. Vehicle (water), AMB, or
AdvAMB suspended in water were administered at the
appropriate dose to rats for 14 days.
Food Rats had access to Purina 5012 rat chow at all times.
Housing Rats were housed singly in cages conforming to
the latest NIH guide for the care and use of laboratory
animals in a temperature-controlled room with a 12 h light/
dark cycle.
Dextran Presentation On day 6 of the study the rats were
treated with the appropriate test article, the water supply
was then removed and replaced by a water bottle con-
taining either 5% DSS (Dextran sulfate sodium: MW:
40,000 Lot# DS40-011, Dextran Products Limited, Scar-
borough, Ontario Canada) dissolved in tap water or tap
water. Approximately 70 ml/rat/day of ﬂuid was provided
from day 6 through the day of necropsy. No other source of
ﬂuids was available. Bottles were reﬁlled daily with fresh
DSS solution or tap water.
Bodyweight and Observation Rats were weighed on days 0,
6, 9, 10, 11, 12, 13 and 14. The consistency of stools
(formed, soft, mixed [soft and diarrhea]) and condition of
the rats were evaluated at that time.
Blood Samples Blood samples (*3.5 ml) were taken by
intraorbital bleeding under isoﬂuorane anesthesia on days 0
and 14 (terminal). Samples were treated in the appropriate
way depending on the analysis.
Blood Studies Aliquots of blood were prepared for the
following analyses.
• Lipid proﬁle (0.5 ml serum): Cholesterol, LDL, HDL
and triglycerides; lipids were analyzed on an Olympus
analyzer.
• Clinical chemistry: ALT (SGPT), AST (SGOT), GGT,
CK, total bilirubin, albumin, total protein, BUN,
creatinine, glucose; 0.5 ml, EDTA blood. Hematology
analyzed on Abbott Cell Dyn 3500.
• Blood cell count: 0.5 ml, EDTA blood and blood
smear; blood cell count analyzed on Abbott Cell Dyn
3500; differential analyzed using Olympus AU2700.
The studies were performed at IDEXX Preclinical Ser-
vices, North Grafton, MA.
Necropsy The study was terminated on day 14 after
obtaining body weights and making observations. Rats
were anesthetized with isoﬂurane. A midline incision was
made and a stool sample was obtained from the rectum or
colon and placed on a slide for testing for occult blood
(Cacogenics Stool Blood Test, SB-21, Single Slide Pro-
fessional Kit, Laboratory Diagnostics Co., Cacogenics,
Morganville, NJ). Occult blood was determined by placing
two drops of the reagent onto the stool sample on the slide
and observing a change of color. The presence of occult
blood was graded using a score of 0, for no color change; 1,
for a very light blue color (±) taking over 30 s to appear; 2,
for a blue color developing in 30 s or more (?); 3, for an
immediate change in color occurring in less than 30 s
(??); and 4, for gross blood observable on the slide. The
colon was gently stretched and the distance from the colo-
cecal junction to the end of the distal rectum was measured
to the nearest 0.1 cm. Five colons from each group were
preserved in 10% buffered formalin and the other ﬁve ﬂash
frozen in a mixture of carbon dioxide and ethanol and
preserved in a -70 C freezer in case histopathology or
analysis of tissue cytokines were required.
Statistical Analysis
The scores for each parameter for each rat were added and
then divided by three to give a DAI score for each rat. The
scores for stool consistency and occult blood for each rat
were added and then divided by two to give a DAINWT
score for each rat (Table 1). Statistical comparisons were
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with Dunn’s multiple comparison tests. The signiﬁcance
level was P\0.05.
For colon length and body weight, comparisons were
done using one-way ANOVA and Bonferroni multiple
comparisons test. The signiﬁcance level was P\0.05.
Statistical Analysis of Clinical Chemistry, CBC,
Differentials, and Lipid Proﬁle Assays
Data (terminal values only) from each individual experi-
mental time point were analyzed by one-way analysis of
variance (ANOVA). For each comparison, the F ratio from
the ANOVA was used to estimate the probability, or P
value, that the data were randomly distributed across
groups. The main effect P value represents the probability
that the experimental groups had no effect on the variable
being tested in that ANOVA. A P value of\0.05 was used
as the cutoff. Dennett’s multiple comparison test was used
for the post hoc comparisons. The low and high dose
treatment groups were compared to the vehicle treated
group and a signiﬁcance level estimated for these com-
parisons. The same water group was used for both AMB
and AdvAMB groups. Prism Version 5.01 (GraphPad
Software, San Diego, CA) was used for all statistical
analyses.
Test Agents
Ambrotose complex (US 37101, Lot # NO7090154) and
Advanced Ambrotose powder (US37601, Lot # NO706
0313) were supplied by Mannatech, Inc. (Coppell, Texas,
USA) (Table 2).
Results
Rats were sacriﬁced on the eighth day of access to DSS in
tap water. Rats receiving oral vehicle and access to DSS
showed signs of diarrhea and bloody stools indicating a
moderate degree of colitis. Rats receiving vehicle, AMB or
AdvAMB plus access to tap water showed no signs of
changes in stool consistency or other signs of colitis.
Disease Activity Index
Rats receiving 5% DSS as the sole source of liquid showed
a signiﬁcant increase in the Disease Activity Index with
and without the weight loss parameter (DAI and DAIN-
WT). Since there was no DSS-associated loss of body
weight, weight loss was not a signiﬁcant factor in deter-
mining the disease index. The DAINWT (DAI without
weight parameter) is a more useful index of the degree of
colitis when weight loss is not observed with DSS treat-
ment. DSS produced a statistically signiﬁcant increase in
both DAI and DAINWT (Table 3). Rats receiving AMB
and AdvAMB and exposed to 5% DSS showed a dose-
related trend to lower indices but a statistically signiﬁcant
inhibition was only noted with the high dose of AdvAMB
(574 mg/kg PO). The DAI and DAINWT scores of all
groups of rats receiving daily administration of vehicle,
AMB, AdvAMB and access only to tap water were similar.
The administration of AMB and AdvAMB in rats allowed
water instead of 5% DSS did not induce any signs of
Table 1 Disease activity index (DAI) and DAI without weight
parameter (DAINWT)
Score Weight loss % Stool consistency Blood in feces
0 0 or gain Normal Negative
1 -1–4.9% Occult blood ±
2 5.0–9.9% Loose stools Occult blood ?
3 10–20% Occult blood ??
4 [20% Diarrhea Gross blood
Table 2 Ambrotose and Advanced Ambrotose compositions averages
Material ingredients Total monosaccharide content % (wt/wt)




Aloe vera gel extract Aloe barbadensis \1 1 2 2 12 5
Arabinogalactan Larix species 8 50 \1
Gum ghatti Anogeissus
latifolia
23 4 1 4 1 6 3
Gum tragacanth Astragalus
gummifer
4 1 17 5 6 10 5 1







a Present only in advance ambrotose
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123intestinal pathology, fecal consistency changes or occult
fecal blood.
Colonic Shortening
DSS produced a statistically signiﬁcant shortening of the
length of the colon in vehicle plus DSS treated groups
(Fig. 1). Statistically signiﬁcant inhibition of DSS-induced
colonicshorteningwasobservedwiththe377 mg/kgdoseof
AMBandbothdosesofAdvAMB(57.4and574 mg/kgPO).
AMB-inhibited DSS induced shortening of colon length by
47% and 53% with 37.7 and 377 mg/kg PO, respectively,
while AdvAMB inhibited shortening 53% and 61% at 57.4
and 574 mg/kg PO, respectively. Treatment with AMB or
AdvAMB in rats with water access instead of 5% DSS had
no effect on colonic length compared to vehicle.
Body Weight
No statistically signiﬁcant changes in body weights were
noted in any of the groups receiving AMB or AdvAMB
with or without exposure to 5% DSS (Table 4).
Blood Studies
DSS treatment itself did not appear to affect hemoglobin or
the absolute number of red blood cells, leukocytes, and
lymphocytes (data not shown). However, exposure to 5%
DSS produced an increase in monocyte count. This
increase was only statistically signiﬁcant when monocyte
counts were calculated as a percent in the vehicle plus tap
water treatment group. AMB signiﬁcantly decreased
monocyte count in DSS-treated rats at 377 mg/kg PO,
while AdvAMB signiﬁcantly decreased the monocyte
count in DSS-treated rats at both 57 and 577 mg/kg PO
(Fig. 2). Neither AMB nor AdvAMB had any effect on
these values in water drinking rats.
Lipid Proﬁle
No statistically signiﬁcant effects were noted due to treat-
ment, DSS administration or treatment with low and high
doses of AMB and AdvAMB on cholesterol, triglycerides,
HDL and LDL levels (data not shown).
Table 3 Effect of Ambrotose and Advanced Ambrotose on disease activity
Daily oral dose (mg/kg) N Mean DAI ± SEM Mean DAINWT ± SEM
Vehicle ? 5% DSS 10 1.8 ± 0.14
a 2.75 ± 0.21
a
AMB 37.7 ? 5%DSS 10 1.63 ± 0.13 2.45 ± 0.20
AMB 377.1 ? 5%DSS 10 1.37 ± 0.14 2.05 ± 0.22
AdvAMB 57.4 ? 5%DSS 10 1.53 ± 0.15 2.3 ± 0.23
AdvAMB 574.3 ? 5% DSS 10 1.20 ± 0.10
b 1.8 ± 0.15
b
Vehicle ? water 10 0.33 ± 0.0 0.5 ± 0.0
AMB 37.7 ? water 10 0.33 ± 0.0 0.5 ± 0.0
AMB 377.1 ? water 10 0.33 ± 0.0 0.5 ± 0.0
AdvAMB 57.4 ? water 10 0.36 ± 0.03 0.55 ± 0.05
Adv AMB 574.3 ? water 10 0.40 ± 0.07 0.6 ± 0.1
DAI disease activity index, DAINWT disease activity index without weight parameter, SEM standard error of the mean, AMB ambrotose complex,
AdvAMB advanced ambrotose powder
a Comparison of vehicle ? tap water to vehicle ? DSS tests. P\0.05 Kruskal–Wallis test with Dunn’s multiple comparison test
b Comparison of vehicle ? DSS to treatments ? DSS tests. P\0.05 Kruskal–Wallis test with Dunn’s multiple comparison test
Fig. 1 Colon length (mean, cm ± SEM) at necropsy after 14 days of
vehicle AMB or AdvAMB and oral dosing plus 8-day access to either
DSS (clear bars) or tap water (dashed bars). Colon length was
signiﬁcantly shortened in the vehicle plus DSS-treated rats compared
to the vehicle plus tap water group. AMB (377 mg/kg PO) and
AdvAMB (57.4 and 574 mg/kg PO) signiﬁcantly inhibited the DSS-
induced colonic shortening.
# Comparison of vehicle ? tap water to
vehicle ? DSS. P\0.05 one-way ANOVA and Bonferroni multiple
comparison test. * Comparison of vehicle ? DSS to treat-
ments ? DSS. P\0.05 one-way ANOVA and Bonferroni multiple
comparison test
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No statistically signiﬁcant effects due to AMB or AdvAMB
treatment plus DSS administration were observed on
albumin, BUN, creatinine, glucose, ALT, AST, CK, and
GGT (data not shown).
Discussion
Chronic daily oral dosing of AMB or AdvAMB dosed prior
to and concomitantly with DSS signiﬁcantly inhibited
colitis produced by replacement of drinking water with a
solution of 5% DSS. AMB and AdvAMB lowered the
incidence of diarrhea and occult blood in the feces as
indicated by a decrease in the DAI. This was especially
evident when the weight parameter was not used (DAIN-
WT). The rats used in the study averaged between 300 and
350 g in order to provide sufﬁcient blood for the analysis.
The colitis produced was less severe than seen in smaller
rats and mice. A longer exposure to DSS would likely have
produced signiﬁcant weight loss. There have been no
published studies, to our knowledge, using rats of equiva-
lent size in a DSS colitis model.
Shortening of the colon has been described in rats or
mice receiving DSS [12, 14]. The cause of this shortening
has not been fully explained, but is a consistent ﬁnding in
animal models of colitis. Using this criterion, both doses of
AdvAMB and the high dose of AMB signiﬁcantly inhibited
the shortening in a dose-related manner. The percent
inhibition was dose related and was greater than 47% for
all doses. This inhibition is similar to or greater than that
observed in studies with agents known to be effective
clinically [15].
DSS was shown to produce a signiﬁcant increase in
monocyte count that was inhibited by AMB and AdvAMB.
This effect was even more prominent if results were ana-
lyzed as a percent of mean monocyte count in the vehicle
plus water group. The only signiﬁcant changes in blood
components in rats having access to either DSS or water
and treatment with AMB or AdvAMB was a dose-related
decrease in absolute monocyte counts. The effect on
monocytes is especially interesting since Grip et al. [18]
Table 4 Change in mean body weight
Treatment mg/kg PO Mean body weight grams ± SEM
Day 0 % Day 12 % Day 13 % Day 14 %
Vehicle water ? DSS 345 ± 4.7 100 ± 0 400 ± 5.4 116 ± 2.1 403 ± 5.0 117 ± 1.9 403 ± 5.0 117 ± 1.9
AMB 37.7 ? DSS 349 ± 5.4 100 ± 0 403 ± 6.0 115 ± 0.9 406 ± 5.4 116 ± 0.9 402 ± 3.8 115 ± 1.5
AMB 377.1 kg ?DSS 349 ± 5.1 100 ± 0 405 ± 5.1 116 ± 1.8 408 ± 5.9 117 ± 2.2 408 ± 6.4 117 ± 2.0
AdvAMB 57.4 ? DSS 348 ± 5.1 100 ± 0 392 ± 6.6 113 ± 0.6 396 ± 7.1 114 ± 1.0 399 ± 7.4 115 ± 0.9
AdvAMB 574.3 ?% DSS 344 ± 5.1 100 ± 0 393 ± 6.1 114 ± 1.3 398 ± 5.7 116 ± 1.4 397 ± 7.4 115 ± 1.7
Vehicle water ? water 347 ± 2.9 100 ± 0 404 ± 5.3 117 ± 1.1 405 ± 6.8 117 ± 1.6 405 ± 6.8 117 ± 1.6
AMB 37.7 ? water 348 ± 4.7 100 ± 0 409 ± 9.4 117 ± 1.9 413 ± 9.4 119 ± 1.8 414 ± 9.1 119 ± 1.8
AMB 377.1 ? water 349 ± 4.5 100 ± 0 403 ± 6.9 115 ± 1.5 404 ± 7.2 116 ± 1.5 406 ± 7.5 117 ± 1.6
AdvAMB 57.4 ? water 346 ± 4.3 100. ± 0 403 ± 4.2 117 ± 2.0 407 ± 4.3 118 ± 1.9 409 ± 4.3 118 ± 1.7
AdvAMB 574.3 ? water 348 ± 5.5 100 ± 0 408 ± 10 117 ± 1.7 412 ± 11 118 ± 1.8 417 ± 11 120 ± 1.9
Change in rat body weight (mean ± SEM) and mean ± SEM percent of baseline weights. Percentage body weight was calculated using day 0
weight as the denominator
Fig. 2 Monocyte count calculated as a mean percent ± SEM of the
mean count in the vehicle plus tap water group at necropsy after
14 days of vehicle AMB or AdvAMB and oral dosing plus 8-day
access to either DSS (clear bars) or water (dashed bars). Percent
monocyte count was signiﬁcantly increased in the vehicle plus DSS
treated rats compared to the vehicle plus tap water group. AMB at
377 mg/kg PO and AdvAMB at 57.4 and 574 mg/kg PO daily
signiﬁcantly inhibited the mean percent of control monocyte count in
DSS-induced treated rats.
# Comparison of vehicle ? tap water to
vehicle ? DSS. P\0.05 one-way ANOVA ? Dunnett’s test.
* Comparison of vehicle ? DSS to treatments ? DSS. P\0.05
one-way ANOVA ? Dunnett’s test
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123indicated that gut-resident and circulating monocytes are
thought to be required for the initiation and maintenance of
inﬂammatory bowel diseases.
The second portion of the study was designed to evaluate
the safety of AMB and AdvAMB plus tap water when
administered daily for 14 days. No signiﬁcant changes in
any of the parameters studied were observed. There were no
treatment-related changes in body weight and no indication
of any observation of gross pathology in the colon. Rats
receiving low and high doses of AMB or AdvAMB and
having access to tap water throughout the study showed no
signiﬁcant change in any of the disease indexes compared to
vehicle, no indication of change in feces consistency or
occult blood in the feces, nor any changes in colonic length.
All control animals, as well as those dosed, had a minimal
positive response in the occult blood test. This may have
been due to the lab chow they were fed as undigested chow
produces a positive result in the occult blood assay (data not
shown). All blood values, clinical chemistry and cytokine
analysis were within the control range.
Several of the components of AMB and AdvAMB have
been shown to have effects on inﬂammatory diseases of the
gastrointestinal tract either in animal models or on human
disease. Langmead et al. [1] evaluated the gel from the aloe
plant administered orally in a double-blind, randomized,
placebo-controlled trial in the treatment of mild to moderate
ulcerative colitis in 44 hospital out-patients given oral aloe
vera gel (100 ml aloe vera gel) or placebo solution. Clinical
remission, improvement and response occurred in nine of
30 patients given aloe vera, compared with one of 14
patients taking placebo. The Simple Clinical Colitis
Activity Index and histological scores decreased signiﬁ-
cantly during treatment with aloe vera, but not with placebo.
They concluded that oral aloe vera gel taken for 4 weeks
produced a clinical response more often than placebo; it
also reduced the histological disease activity and appeared
to be safe. Langmead et al. [2] also showed a dose-depen-
dent inhibitory effect on reactive oxygen metabolite pro-
duction in an in vitro study using human colonic cells
inhibiting the production of prostaglandin E2, but without
effects on thromboxane B2 production. Aloe vera treatment
(200 mg/kg PO) reduced leukocyte adherence and TNFc
level, elevated IL-10 level and promoted gastric ulcer
healing. Korkina et al. [19] evaluated the effects of a natural
antioxidant preparation based on aloe vera and ubiquinone
for potential activity against DSS-induced colonic inﬂam-
mation and alterations of the intestinal electrophysiological
activity and motility. They used 5% dextran sulfate for
3 days, followed by 1% DSS for 4 days administered in
drinking water. Lipoperoxidation, superoxide production,
glutathione peroxidase, glutathione-S-transferase activities,
and reduced glutathione content increased, and superoxide
dismutase and catalase activities were sharply suppressed in
colon tissue. Inﬂammation, electrical/mechanical impair-
ment in the gut, and most of the oxidative stress parameters
were improved substantially by pre-treatment, but not by
simultaneous or post treatment.
Arabinogalactan has been reported to have positive
effects on fecal chemistry [16]. Arabinogalactan is a non-
digestible soluble dietary ﬁber that resists hydrolytic
enzyme action and enters the large bowel intact where it is
fermented by resident microﬂora. The effect of 15 and 30 g
orally per day of a commercially available arabinogalactan
from Western Larch produced signiﬁcant increases in total
fecal anaerobes. A signiﬁcant increase in Lactobacillus
spp. was observed when subjects consumed arabinogalac-
tan for a total of 6 weeks with no signiﬁcant changes in
other microﬂora, fecal enzyme activity, transit time, fre-
quency, fecal weight, fecal pH and short-chain fatty acids.
Matsumoto et al. [20] showed that fucoidans derived
from Cladosiphon okamuranus Tokida ameliorates chronic
colitis in the rat through the down-regulation of interleu-
kin-6 production on colonic epithelial cells. Previous
studies showed the interleukin (IL-6 STAT-3) signal was
up-regulated in inﬂammatory bowel disease in both
humans and animal models [21]. Fucoidan treatment
caused a decrease in the DAI, and myeloperoxidase activity
decreased in mice fed Cladosiphon fucoidan, but not Fucus
fucoidan. The levels of IL-6 mRNA in colonic epithelial
cells were lower in colitis-induced Balb/c mice fed
Cladosiphon fucoidan than those fed a standard diet.
Fucoidan improves mouse chronic colitis by down
regulating the synthesis of IL-6 in the colonic epithelial
cells. The authors concluded that fucoidan derived from
C. Tokida might be useful as a dietary substance for
patients with inﬂammatory bowel disease.
Rice starch type 3 (115 g/kg) was shown to block DSS-
induced colonic shortening in rats after 7 days of dosing
while fructo-oligosaccharides did not [22]. Rice starch is a
substrate yielding high levels of butyrate [5]. Butyrate is
recognized to be effective in patients with Crohn’s disease
and ulcerative colitis when administered by enema [23];
however, the effect is not present when given orally [24].
Sprague-Dawley rats received water or DSS and ceco-
colonic inﬂammatory injuries assessed macroscopically
and histologically. At days 7 and 14, cecal and distal
macroscopic and histological observations were improved
in rice starch plus DSS and the butyrate levels were higher
in the cecum of the rice starch plus DSS rats.
Glucosamine has been observed to decrease proinﬂam-
matory cytokine-induced ICAM-1 production in human
conjunctival cells in vitro [25] and inhibit TNFa and IFNc-
induced production of ICAM 1 in human retinal cells in
vitro [26]. Although these studies were not done in gas-
trointestinal tissue, ICAM 1 has been implicated in pro-
duction of DSS-induced colitis in mice [15]. Glucosamine
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gastric lesions in rats [6], signiﬁcantly prevented ibupro-
fen-induced depletion of protein and glycoprotein compo-
nents and maintained the activities of membrane-bound
ATPases as compared to the untreated ulcer induced group
of rats. The authors ascribe the effectiveness of glucosa-
mine in part to strengthening the mucosal barrier by
increasing mucosal glycoprotein synthesis and to its free
radical scavenging property.
AMB and AdvAMB both were effective in interfering
with the pathological effects of 5% DSS-induced colitis in
the rat. Although the colitis was not severe, shortening of
the colon, the presence of occult blood in the feces and
either a change in consistency of the fecal pellets or diar-
rhea were noted. All these were attenuated by daily dosing
of AMB and AdvAMB. The low doses tested were
equivalent to the usual human dose.
Polysaccharides found in aloe vera have been reported
to have antiviral, antibacterial, antifungal and antitumor
activity [27]. This and the multiple effects of the other
components of AMB and AdvAMB on butyrate, ICAM-1,
TNFc, etc. may be additive and have a positive effect on the
pathology and symptoms of IBD. A combination of these
plant-derived materials may be more effective than any one
administered alone. However, this conclusion would
require additional testing of the individual components.
Daily oral dosing with AMB and AdvAMB were both
shown to have signiﬁcant effects in inhibiting DSS-induced
colitis in rats at doses that are safe, even when administered
at multiples of the human dose for 14 days. Administration
of either of these formulations may be useful in improving
the quality of life in IBD patients.
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